唑来磷酸治疗西北高原地区骨质疏松症的临床研究  

Clinical Effect of Zoledronic Acid to Treat the Syndrome of Osteoporosis in Northwest Highland Area

作　　者：窦强 高杰[1] 李志琳 杨成伟[1] 蓝旭[1] 

机构地区：[1]中国人民解放军兰州军区兰州总医院全军创伤骨科研究所脊柱外科,730050

出　　处：《医学研究杂志》2017年第11期121-123,共3页Journal of Medical Research

摘　　要：目的观察唑来磷酸治疗骨转移骨质疏松的临床疗效。方法选取笔者医院2011年4月~2015年6月118例肿瘤骨转移后骨质疏松患者,伴有疼痛症状,随机分为研究组60例(静脉滴注唑来磷酸注射液),对照组58例(口服骨化三醇片)。共2个疗程,1年为1个疗程。结果通过椎骨骨密度比较,研究组治疗前后有统计学意义(P﹤0.05),与对照组比较,治疗后12个月、治疗结束后(24个月)差异有统计学意义(P<0.05);与对照组比较,研究组在改善生活质量与镇痛效果上差异有统计学意义(P<0.05);对初次使用唑来磷酸患者,经用药24h前后Pd值比较差异有统计学意义(P<0.05);对骨代谢生化指标比较,两组用药前后,血钙值、BGP和CTX比较差异有统计学意义(P<0.05)。结论唑来磷酸可明显增加患者骨密度,改善骨质疏松,减轻患者疼痛。Objective To observe the clinical effect of zoledronic acid to treat cancer bone metastases with osteoporosis.Methods From April 2011 to June 2015,118 cases of cancer bone metastases with osteaparosis and ache were divided into two groups according to the random number table. The reserch group（60 cases） were given zoledronic acid only, while the control group（58 cases） calcitiol. 2 period of treatment, 1 year for 1 course of treatment.Results After and pre of treatment, The BMD of vertebra of reserch group,the difference was statistically significant（P〈0.05）. And after 12 months and 24 months, compared with the control group, the difference was statistically significant（P〈0.05）.The life quality and the pain in research group, compared with the control group, the difference was statistically significant（P〈0.05）.After 24h using zoledronic acid,the changes of Pd was statistically significant（P〈0.05）.The Blood calcium,BGP and CTX, compared with the control group, the difference was statistically significant（P〈0.05）.Conclusion Zoledronic acid can increase the BMD, improve the syndrome of osteoporosis, and relieve the pain of patients.

关 键 词：唑来磷酸 骨质疏松 骨密度 临床疗效 

分 类 号：R4[医药卫生—临床医学]